142 related articles for article (PubMed ID: 23806740)
1. Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy.
Cammarota S; Bruzzese D; Catapano AL; Citarella A; De Luca L; Manzoli L; Masulli M; Menditto E; Mezzetti A; Riegler S; Putignano D; Tragni E; Novellino E; Riccardi G
Nutr Metab Cardiovasc Dis; 2014 Jan; 24(1):10-7. PubMed ID: 23806740
[TBL] [Abstract][Full Text] [Related]
2. Lower rate of cardiovascular complications in patients on bolus insulin analogues: a retrospective population-based cohort study.
Cammarota S; Falconio LM; Bruzzese D; Catapano AL; Casula M; Citarella A; De Luca L; Flacco ME; Manzoli L; Masulli M; Menditto E; Mezzetti A; Riegler S; Novellino E; Riccardi G
PLoS One; 2013; 8(11):e79762. PubMed ID: 24244557
[TBL] [Abstract][Full Text] [Related]
3. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
Juhaeri J; Gao S; Dai WS
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
[TBL] [Abstract][Full Text] [Related]
4. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
[TBL] [Abstract][Full Text] [Related]
5. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
6. Macro- and microvascular outcomes in patients with type 2 diabetes treated with rapid-acting insulin analogues or human regular insulin: a retrospective database analysis.
Rathmann W; Schloot NC; Kostev K; Reaney M; Zagar AJ; Haupt A
Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):92-9. PubMed ID: 24558019
[TBL] [Abstract][Full Text] [Related]
7. Micro- and macrovascular outcomes in Type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis.
Kress S; Kostev K; Dippel FW; Giani G; Rathmann W
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):821-9. PubMed ID: 22578200
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
Chang CH; Toh S; Lin JW; Chen ST; Kuo CW; Chuang LM; Lai MS
PLoS One; 2011; 6(6):e21368. PubMed ID: 21738645
[TBL] [Abstract][Full Text] [Related]
9. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM;
Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
[TBL] [Abstract][Full Text] [Related]
10. Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin.
Kostev K; Dippel FW; Rockel T; Siegmund T
J Wound Care; 2012 Oct; 21(10):483-4, 486-9. PubMed ID: 23103482
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
12. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
13. Comparative risks of diabetes-related complications of basal insulins: a longitudinal population-based cohort of type 1 diabetes 1999-2013 in Taiwan.
Ou HT; Lee TY; Du YF; Li CY
Br J Clin Pharmacol; 2018 Feb; 84(2):379-391. PubMed ID: 29073329
[TBL] [Abstract][Full Text] [Related]
14. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Reynolds MW
Curr Med Res Opin; 2012 Jun; 28(6):991-7. PubMed ID: 22519390
[TBL] [Abstract][Full Text] [Related]
15. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
Lind M; Fahlén M; Eliasson B; Odén A
Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
18. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
19. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
[TBL] [Abstract][Full Text] [Related]
20. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]